CAS: 90566-53-3; Fluticasone

该化合物是一种主要用于其抗炎和免疫抑制特性的合成花生类固醇,通常用于治疗哮喘和慢性阻塞性肺病(COPD)等呼吸状况,以及过敏性鼻炎和皮肤紊乱,其特征是,氟丙酮对葡萄素受体具有高度的亲和性,允许其有效地调节基因表达方式并抑制灭炎性介质的释放;氟丙酮通常存在于各种配方中,包括吸入器,鼻喷剂和热液奶油,在临床应用中强化其多功能性;其化学结构具有氟甲状腺骨的特征,有助于其烈性和长期作用;该化合物一般都具有很强的效应,尽管其潜在的副作用可能包括局部刺激或长期使用系统效应;由于其功效和安全性,氟丙酮仍然是一种广泛规定的治疗炎症的药物.

结构式图片

欧盟法规

C&L通报

上下游产品

S-iodomethyl 6α,9α-difluoro-11β,17α-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(propionyloxy)androsta-1,4-diene-17β-carboxylic acid

合成工艺路线路线简述

  • 1174034-80-0 = 90566-53-3
    反应条件:1.1 Reagents: Silver Fluoride Solvents: Acetonitrile; 3 H,Rt
    标题:Synthesis Of Substances Related To Fluticasone Propionate
    作者:Zheng,Jin; Lai,Qinglin; Dai,Yiru; Zhao,Qingjie; Shen,Jingshan
    参考文献:Organic Preparations And Procedures International 日期:2008 卷标:40(6) 页码:566-571
S-Iodomethyl 6α,9α-Difluoro-11β,17α-Dihydroxy-16α-Methyl-3-Oxoandrosta-1,4-Diene-17β-Carbothioate置于silver Fluoride体系中,用 乙腈 作为反应溶剂,化学反应 3.0H,以82%的收率获得产物氟替卡松
参考文献:丙酸氟替卡松相关物质的合成
标题:丙酸氟替卡松相关物质的合成
摘要:6. (A) W. Vetter 和 J. Wu,Chemosphere 52,423 (2003);(B) El Teuten,Be Pedler,An Hangsterfer 和 Cm Reddy,Environ.污染.144,336 (2006);(C) El Teuten,R. Saintlouis,Be Pedler,L. Xu,E. Pelletier 和 C. M. Reddy,Mar. Polfur.公牛.52,572 (2006);(D) W. Vetter,S. Gaul,D. Olbrich 和 C. Gaus,Chemosphere 66,201 1 (2007); (E) El Teuten 和 Cm Reddy,Environ.污染.145,668 (2007);(F) K. Pangallo,Rk Nelson,El Teuten,Be Pedler 和
DOI:10.1080/00304940809458122

海关参考信息

专利信息


专利号:US-9315483-B2
优先权日:2007-09-13
标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT
权利人:CONCERT PHARMACEUTICALS INC
摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.

专利号:US-2024082118-A1
优先权日:2021-05-19
标 题:Topical compositions and methods of preparing the same
发明人:ABRAMOVICH SAGI; AVIDOR GAL; LANDA BENZION
权利人:LANDA LABS 2012 LTD
摘要:There is disclosed a composition comprising a water-insoluble thermoplastic compound capable of stimulating collagen synthesis (CSSC), the CSSC having a molecular weight of more than 0.6 kDa and being dispersed in a polar carrier as nano-elements having an average diameter of 200 nm or less and a viscosity of 107 mPa·s or less. The nano-elements of CSSC can be capable of stimulating the synthesis of skin proteins and/or enabling the delivery of active agents upon their application to a surface to be treated therewith. Methods for preparing the compositions and uses thereof are also provided.

专利号:US-2006009435-A1
优先权日:2004-06-23
标 题:Synthesis and powder preparation of fluticasone propionate
发明人:KASPI JOSEPH; ARAD ODED; BRAND MICHAEL; SHOOKRUN MOTY; MALKA SIMONA; ALNABARI MOHAMMED; HAZAN SHALOM; MALESEVIC VLADO
权利人:KASPI JOSEPH; ARAD ODED; BRAND MICHAEL; SHOOKRUN MOTY; MALKA SIMONA; ALNABARI MOHAMMED; HAZAN SHALOM; MALESEVIC VLADO
摘要:An improved process for preparing fluticasone propionate, performed in the presence of water, is disclosed. Further disclosed is a process for preparing a fluticasone propionate that is highly suitable for administration by inhalation. Further disclosed are fluticasone propionate and a powdered fluticasone propionate prepared by these processes and pharmaceutical compositions for administration by inhalation containing same. A process of purifying a key intermediate in the synthesis of fluticasone propionate is also disclosed.

专利号:US-7208613-B2
优先权日:2002-06-20
标 题:Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
发明人:JADAV KANAKSINH JESINGBHAI; KAMBHAMPATI SUDHAKAR; CHITTURI TRINADHA RAO; THENNATI RAJAMANNAR
权利人:SUN PHARMACEUTICAL IND LTD
摘要:The present invention provides a convenient process for the preparation of S-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate, a compound of formula 1, comprisingn (a) treating 17β-[(N,N-dimethylcarbamoyl)thio]carbonyl-6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene, a compound of formula 3 with alkali metal carbonate-alcohol system to obtain 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioic acid, a compound of formula 4; (b) reacting the compound of formula 4 with bromofluoromethane to yield the compound of formula 1.

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-8802660-B2
优先权日:2007-03-12
标 题:De novo synthesis of glucocorticoids in the epidermis and its uses and applications
发明人:TOMIC-CANIC MARJANA; BREM HAROLD; SAMUELS HERBERT H
权利人:TOMIC-CANIC MARJANA; BREM HAROLD; SAMUELS HERBERT H; UNIV NEW YORK
摘要:The present invention relates to methods and compositions that control, i.e., antagonize/inhibit or agonize/stimulate, de novo glucocorticoid production in the skin. Such methods and compositions can be used for the prevention and/or treatment of a variety of skin conditions, including inflammation, acute wounds, chronic non-healing wounds, keloid, fibrotic or hypertrophic scars, and epithelial-derived cancer.
山东泰华生物科技股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.taihuapharm.com
企业联系电话:0538-8935055; 8933586; 5073168👤
📞山东泰华生物科技股份有限公司 ⚠️参考联系方式
联系人:张芹
电话:0538-8935055; 8933586; 5073168

传真:0538-8935056
邮箱:sales@taihuapharm.com
通信地址: 山东省泰安市高新区配天门大街399号
邮编: 271000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:山东省泰安市高新区配天门大街399号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1. Zhang M, Si SJ, Dai WJ, Yang J, Wang Y, Wei XR, Liu S, Xu CY, Zhang C, Jin F, Jiang LQ. A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment. Colloids Surf B Biointerfaces. 2023 May 24;228:113364. doi: 10.1016/j.colsurfb.2023.113364. Epub ahead of print.
14:1184552. doi: 10.3389/fphar.2023.1184552. 3. Passali D, Passali GC, Damiani V, Ciprandi G. Azelastine/fluticasone and allergic rhinitis in clinical practice. Eur Arch Otorhinolaryngol. 2023 Jun 5. doi: 10.1007/s00405-023-08006-9. Epub ahead of print. 15(4):e38334. doi: 10.7759/cureus.38334. 6. Oosterholt S, Pavord ID, Brusselle G, Yorgancıoğlu A, Pitrez PM, Abhijith PG, Teli C, Pasqua OD. Modelling Asthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomised clinical trials. Br J Clin Pharmacol. 2023 May 23. doi: 10.1111/bcp.15801. Epub ahead of print. 8. Lee EG, Kim Y, Hwang YI, Yoo KH, Lee SE, Jung KY, Lee D, Park YB, Rhee CK. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. Sci Rep. 2023 May 20;13(1):8183. doi: 10.1038/s41598-023-35223-3. 9. Syverson EP, Tobin M, Patton T, Franciosi JP, Gupta SK, Venkatesh RD. Variability in Swallowed Topical Corticosteroid Practice Patterns for Treatment of Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 May 18. doi: 10.1097/MPG.0000000000003834. Epub ahead of print. TRACK (Triple therapy for Japanese with mild to moderate COPD in Kyushu) study investigator group. Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study. BMJ Open Respir Res. 2023 May;10(1):e001607. doi: 10.1136/bmjresp-2022-001607.
314:104072. doi: 10.1016/j.resp.2023.104072. Epub ahead of print.
14:1131949. doi: 10.3389/fphys.2023.1131949. 13. Castro K, Arostegui D, Schwarz S, Gandhi S, Peshimam J, Rabinowitz S, Pittman M, Wallach T. Histologically Remarkable Eosinophilic Esophagitis Responsive to Dupilumab in a Gastrostomy Tube-Dependent Pediatric Patient on Amino Acid Formula. JPGN Rep. 2022 Sep 1;3(4):e250. doi: 10.1097/PG9.0000000000000250. 14. Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History. Int J Chron Obstruct Pulmon Dis. 2023 Apr 19;18:625-641. doi: 10.2147/COPD.S386962. 15. Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. J Manag Care Spec Pharm. 2023 May

合成参考文献


参考文献:10.1272/jnms.77.21
摘要:Nonaka M, Sakanushi A, Kusama K, Ogihara N, Yagi T. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J Nippon Med Sch. 2010 Feb;77(1):21–8. doi: 10.1272/jnms.77.21.
摘要:Patel M, Perrin K, Beasley R. Beta agonist use during asthma exacerbations: how much is too much N Z Med J. 2011 Apr 15;124(1332):77–80.
参考文献:10.2147/opth.s6541
摘要:Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol. 2011;5():811–6.
参考文献:10.1007/s00535-011-0435-5
摘要:Fujishiro H, Amano Y, Kushiyama Y, Ishihara S, Kinoshita Y. Eosinophilic esophagitis investigated by upper gastrointestinal endoscopy in Japanese patients. J Gastroenterol. 2011 Sep;46(9):1142–4. doi: 10.1007/s00535-011-0435-5.
参考文献:10.1002/ppul.21499
摘要:Pedersen S, Maspero J, Gul N, Sharma R. Components of asthma control and treatment response of individual control criteria in children: analysis of the PEACE study. Pediatr Pulmonol. 2011 Dec;46(12):1182–8. doi: 10.1002/ppul.21499.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知